Literature DB >> 8759949

Toward optimizing the clinical utility of distortion product otoacoustic emission measurements.

L Stover1, M P Gorga, S T Neely, D Montoya.   

Abstract

This study examined the effect of primary stimulus level on the ability of distortion product otoacoustic emission (DPOAE) measurements to separate normal-hearing from hearing-impaired ears. Complete I/O functions were obtained for nine f2 frequencies on 210 people approximately evenly divided between normal hearing and hearing impaired. Clinical decision theory was used to assess both DPOAE amplitudes and DPOAE threshold as diagnostic indicators of hearing status. Moderate level primary stimuli elicited responses that separated normal from impaired better than either lower level or higher level stimuli. The two populations were differentiated for all frequencies above 500 Hz by DPOAE amplitude, given primary levels, L1 and L2, of 65 and 55 dB SPL. DPOAE threshold performed equally well, but threshold ambiguity in noise and longer testing times make it a less suitable DPOAE measure to use diagnostically.

Entities:  

Mesh:

Year:  1996        PMID: 8759949     DOI: 10.1121/1.416207

Source DB:  PubMed          Journal:  J Acoust Soc Am        ISSN: 0001-4966            Impact factor:   1.840


  31 in total

1.  Influence of calibration method on distortion-product otoacoustic emission measurements: I. test performance.

Authors:  Sienna R Burke; Abigail R Rogers; Stephen T Neely; Judy G Kopun; Hongyang Tan; Michael P Gorga
Journal:  Ear Hear       Date:  2010-08       Impact factor: 3.570

2.  Cochlear Reflectance and Otoacoustic Emission Predictions of Hearing Loss.

Authors:  Stephen T Neely; Sara E Fultz; Judy G Kopun; Natalie M Lenzen; Daniel M Rasetshwane
Journal:  Ear Hear       Date:  2019 Jul/Aug       Impact factor: 3.570

3.  A validation and potential clinical application of multivariate analyses of distortion-product otoacoustic emission data.

Authors:  Michael P Gorga; Darcia M Dierking; Tiffany A Johnson; Kathryn L Beauchaine; Cassie A Garner; Stephen T Neely
Journal:  Ear Hear       Date:  2005-12       Impact factor: 3.570

4.  Influence of primary-level and primary-frequency ratios on human distortion product otoacoustic emissions.

Authors:  Tiffany A Johnson; Stephen T Neely; Cassie A Garner; Michael P Gorga
Journal:  J Acoust Soc Am       Date:  2006-01       Impact factor: 1.840

5.  Distortion product otoacoustic emissions: cochlear-source contributions and clinical test performance.

Authors:  Tiffany A Johnson; Stephen T Neely; Judy G Kopun; Darcia M Dierking; Hongyang Tan; Connie Converse; Elizabeth Kennedy; Michael P Gorga
Journal:  J Acoust Soc Am       Date:  2007-12       Impact factor: 1.840

6.  Low-frequency and high-frequency cochlear nonlinearity in humans.

Authors:  Michael P Gorga; Stephen T Neely; Darcia M Dierking; Judy Kopun; Kristin Jolkowski; Kristin Groenenboom; Hongyang Tan; Bettina Stiegemann
Journal:  J Acoust Soc Am       Date:  2007-09       Impact factor: 1.840

7.  Meta-Analysis of Distortion Product Otoacoustic Emission Retest Variability for Serial Monitoring of Cochlear Function in Adults.

Authors:  Kelly M Reavis; Garnett P McMillan; Marilyn F Dille; Dawn Konrad-Martin
Journal:  Ear Hear       Date:  2015 Sep-Oct       Impact factor: 3.570

8.  Distortion-product otoacoustic emission test performance for ototoxicity monitoring.

Authors:  Kelly M Reavis; Garnett McMillan; Donald Austin; Frederick Gallun; Stephen A Fausti; Jane S Gordon; Wendy J Helt; Dawn Konrad-Martin
Journal:  Ear Hear       Date:  2011-02       Impact factor: 3.570

9.  Multivariate DPOAE metrics for identifying changes in hearing: perspectives from ototoxicity monitoring.

Authors:  Dawn Konrad-Martin; Kelly M Reavis; Garnett P McMillan; Marilyn F Dille
Journal:  Int J Audiol       Date:  2012-02       Impact factor: 2.117

10.  Changes in the DP-gram during the preterm and early postnatal period.

Authors:  Carolina Abdala; Sandra I Oba; Rangasamy Ramanathan
Journal:  Ear Hear       Date:  2008-08       Impact factor: 3.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.